Objective: To investigate the association between estimated GFR (eGFR) and all-cause mortality, including the contribution of temporal eGFR changes, in well-characterised community-based patients with type 2 diabetes. Design: Longitudinal observational study. Methods: Participants from the Fremantle Diabetes Study Phase 1 were assessed between 1993 and 1996 and followed until end-December 2012. Cox proportional hazards modelling was used to assess the relationship between baseline eGFR category (Stage 1-5) and all-cause death, and between eGFR trajectories assigned by semiparametric group-based modelling (GBM) and all-cause death in patients with five post-baseline annual eGFR measurements. Results: In the full cohort (1296 patients; mean ± s.d. age 64.1 ± 11.3 years, 48.6% males), 738 (56.9%) died during 12.9 ± 6.1 years of follow-up. There was a U-shaped relationship between all-cause death and eGFR category. With Stage 3 (45-59 mL/min/1.73 m 2 ) as reference, the strongest association was for eGFR ≥90 mL/min/1.73 m 2 (hazard ratio (95% CI) 2.01 (1.52-2.66); P < 0.001). GBM identified four linear trajectories ('low', 'medium', 'high', 'high/declining') in 532 patients with serial eGFR measurements. With medium trajectory as reference, eGFR trajectory displaced baseline eGFR category as an independent predictor of death, with low and high/declining trajectories associated with more than double the risk (2.03 (1.30-3.18) and 2.24 (1.31-3.83) respectively, P ≤ 0.003) and associated median reductions in survival of 6.5 and 8.7 years respectively. Conclusion: There is a nonlinear relationship between eGFR and death in type 2 diabetes, which is at least partially explained by a sub-group of patients with an initially high but then rapidly declining eGFR.
Introduction those with glomerular hyperfiltration (an eGFR ≥125 to ≥140 mL/min/1.73 m 2 by isotopic measurement in various studies) (3) which has a debated but likely association with more rapid progression of diabetic nephropathy (4) and which may also be an independent predictor of mortality in the general population (5) . The evidence that eGFR has a U-shaped association with mortality, including diabetes, questions the validity of studies which have assessed the prognostic significance of renal disease in statistical models assuming simple linearity or using categorisation that belies the complexity of the relationship. In addition, there is emerging evidence from general population (6) and diabetes (7, 8) studies that a single eGFR does not identify patients in whom a subsequent relatively rapid decline from baseline also portends an adverse prognosis. This sub-group could explain the U-shaped relationship with death observed in studies utilising only baseline eGFR, since those patients with a relatively high initial eGFR could either progress quickly to renal impairment and death or maintain renal function with an associated favourable outcome.
This hypothesis has not been investigated in the general population or in the specific case of type 2 diabetes. Its evaluation would require longitudinal follow-up of a well-characterised community-based sample with clearly identified outcomes, minimal attrition and an adequate duration of follow-up. In addition to conventional modifiable risk factors for renal disease such as hypertension and glycaemia, the availability of genetic determinants would strengthen such an analysis. In the case of diabetic renal disease, these would include polymorphisms of the ACE (9), angiotensin II type 1 receptor (AT1R) (10) , apolipoprotein E (APOE) (11) and methylenetetrahydrofolate reductase (MTHFR) (12) genes.
A valid method of assigning individuals to categories of changes in renal function over time would also be essential (6) . Temporal changes in variables can be characterised using latent class analysis which identifies distinctive clusters of individual trajectories in a larger sample, with the simplest model of best fit selected statistically (13, 14) . This group-based modelling (GBM) approach has been used to differentiate groups of patients by time-related changes in key variables in disease contexts such as public health (15) , psychiatry (16) and metabolic disorders (17, 18) , and in the categorisation of changes in HbA 1c in diabetes (19, 20) including FDS1 (21) .
To determine whether, in well-characterised, representative, population-based patients with type 2 diabetes, there is evidence of (i) a U-shaped relationship between baseline eGFR and mortality and (ii) sub-groups of patients defined by GBM in which a relatively rapid fall in eGFR is independently associated with death, we have analysed long-term serial eGFR and mortality data from the Fremantle Diabetes Study Phase 1 (FDS1).
Subjects and methods

Study design, setting, patients and approvals
The FDS1 is a natural history study in a postcodedefined urban community of 120 097 people in the state of Western Australia (WA). The FDS1 protocol was approved by the Fremantle Hospital Human Research Ethics Committee, and all subjects gave written informed consent. Descriptions of recruitment and details of non-recruited patients have been published (22) . Of 2258 diabetic patients identified from hospital clinic and inpatient lists, local physician referrals, allied health facilities, pharmacies, opticians, advertising in local media and word of mouth between 1993 and 1996, 1426 (63%) entered the FDS1 of whom 1296 (91%) had type 2 diabetes based on age at diagnosis, history of insulin treatment, adiposity and islet autoantibody status if required (23) . Eligible patients who were not recruited were a mean of 1.4 years older than participants, but their sex distribution and the distributions of diabetes types and blood glucoselowering treatments were similar (22, 23) .
The aim of FDS1 was for five annual post-baseline face-to-face assessments, and 532 type 2 patients (41.0%) attended all of these. For these 532 patients, there were only 11 (0.3%) missing eGFR values from the total of 3192 which allowed the most accurate categorisation of eGFR trajectory (see below). This group had a variable period of diagnosed diabetes before FDS1 entry, six standardised assessments including baseline and an average of 10 years further follow-up.
Clinical assessment and laboratory tests
At baseline and annual reviews to November 2001, a detailed multifaceted questionnaire was completed, a physical examination and relevant investigations including electrocardiography were performed, and fasting biochemical tests were carried out in a single nationally accredited laboratory using standardised methods that ensured consistency of measurement over time (22) . Diabetes-related data including duration were Insertion/deletion (I/D) polymorphisms of the ACE gene were detected by validated PCR supplemented by restriction typing of PCR products (27) . The A1166C polymorphism in ATR1 was identified using mutagenically separated PCR, with an A-allele-specific forward primer, a C-allele-specific forward primer and a reverse primer, with separation of PCR products on 3% agarose gel (27) . APOE genotype was determined via PCR amplification and restriction enzyme digestion (28) . Three co-dominant APOE alleles (ɛ2, ɛ3, ɛ4) encode for three different isoforms (E2, E3, E4) with six genotypes. The C677T (rs1801133), a polymorphism in exon 5 of the MTHFR gene resulting in substitution of valine for alanine at position 222, was determined by Hinfl digestion of the PCR products (29) .
Mortality and hospital morbidity data
The WA Data Linkage System (WADLS) includes all hospitalisations in WA since 1970, and all death registrations (30) . The WADLS was linked to the FDS1 database to provide mortality data from the beginning of the study until end-December 2012. Each subject's Charlson Comorbidity Index (CCI) (31), excluding diabetes and its complications, was also calculated from WADLS data.
Statistical analysis
The computer packages IBM SPSS Statistics 21 (IBM) and Stata IC 13.1 (StataCorp) were used for statistical analysis. Data are presented as proportions, mean ± s.d., geometric mean (s.d. range) or, in the case of variables which did not conform to a normal or log-normal distribution, median and (inter-quartile range). For independent samples, two-way comparisons for proportions were by Fisher's exact test, for normally distributed variables by Student's t-test and for non-normally distributed variables by Mann-Whitney U-test. Multiple comparisons for proportions were by Fisher's exact test or chi-squared test, for normally distributed variables by ANOVA and for nonnormally distributed variables by Kruskal-Wallis test. For statistically significant trends, pairwise comparisons were 
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For analysis of predictors of death in all FDS1 type 2 patients, bivariate baseline associates of all-cause death were first determined. Cox proportional hazards modelling, with age as the time scale and left truncation at study entry (employed due to the presence of covariates strongly associated with age) (32), was used to determine independent predictors of all-cause death, excluding eGFR, using interactive forward conditional modelling (P < 0.05 for entry, P > 0.10 for removal) with all clinically plausible variables at P < 0.20 in bivariate analyses considered for entry into the model. After adjustment for the most parsimonious model, conventional eGFR ) were entered. To categorise temporal changes in eGFR during follow-up, GBM was used to identify sub-groups based on heterogeneous longitudinal polynomial eGFR trajectories, an approach we have used previously for HbA 1c (21) . This was implemented using the procedure 'traj' in Stata/IC 13.1 (StataCorp) (14) . The censored normal model was used, with uncensored cases handled by specifying a minimum and maximum outside the range of the observed data values (33) . The number of groups and degree of polynomial in each trajectory group was determined using the Bayesian Information Criterion, which measures improvement in model fit gained by adding additional groups or shape parameters incorporating a penalty for added complexity (13, 14, 34) . Solutions that included small trajectory groups (<5% of the sample) were rejected. To assess model fit, the mean posterior probability of group membership was examined (>0.70 is conventionally recommended).
Cox proportional hazards modelling, with age as the time scale and left truncation at study entry, was used to determine independent predictors of all-cause death in the sub-group with eGFR trajectories using the same strategy as the total sample (developing the most parsimonious model, excluding eGFR and then adding conventional eGFR categories and trajectories to see which, if either, remained in the final adjusted model).
Results
The 1296 FDS1 participants with type 2 diabetes had a mean ± s.d. age of 64.1 ± 11.3 years, 48.6% were males, and their median (inter-quartile range) diabetes duration was 4.0 (1.0-9.0) years. There were 290 patients (22 The 5-year average was calculated for each variable as the mean of all six annual values. For statistically significant trends (P < 0.05), *P < 0.05, **P < 0.01, ***P < 0.001 vs lower eGFR trajectory group; † P < 0.05, † † P < 0.01 vs medium eGFR trajectory group; ‡ P < 0.05, ‡ ‡ P < 0.01, ‡ ‡ ‡ P < 0.001 vs higher eGFR trajectory group, adjusted for multiple pairwise comparisons using the Bonferroni correction.
Table 4 (Continued).
Determinants of mortality
The characteristics of those who died compared with those who survived are summarised in Table 1 . The deceased patients were older, more likely to be male, had diabetes for longer and were more likely to be insulin-treated, had less well-controlled glycaemia and blood pressure, and were more likely to have chronic complications than those who were still alive at the end of follow-up.
The results of Cox proportional hazards modelling are shown in Table 2 . The independent predictors of all-cause death were male gender, current smoking, albuminuria, a high CCI, Aboriginality, increased diastolic blood pressure and body mass index (BMI), schizophrenia and chronic complications (retinopathy, ischaemic heart disease and peripheral arterial disease), while systolic blood pressure was inversely associated. When eGFR category was added to the most parsimonious model, there was a U-shaped relationship in hazard ratios (HRs) with 45-59 mL/min/1.73 m 2 as reference (HR of 1.0), the strongest association (a doubling of risk) being with an eGFR ≥90 mL/min/1.73 m 2 (HR (95% CI) 2.01 (1.52-2.66); P < 0.001).
eGFR trajectories and mortality
Consistent with the requirement for the longitudinal subgroup to have survived ≥5 years after recruitment, these 532 patients were younger at entry and less likely to be insulin-treated, and they had shorter diabetes duration, a lower HbA 1c , fewer vascular complications and a lower mortality during subsequent follow-up than the 764 remaining type 2 FDS1 subjects (P < 0.004; There were four trajectories of eGFR over time identified by GBM which were close to linear and which have been termed 'low', 'medium', 'high' and 'high/ declining' (Fig. 1) . The mean ± s.d. probability of eGFR trajectory group membership was 0.91 ± 0.12 for the low trajectory, 0.91 ± 0.13 for the medium trajectory, 0.91 ± 0.14 for the high trajectory, and 0. were no patients with hyperfiltration at baseline in the low and medium trajectory groups, while 18 (7.0%) and 7 (14.3%) patients in the high and high/declining groups respectively had hyperfiltration on age-adjusted criteria (P < 0.001 by Fisher's exact test). The characteristics of the patients in the four trajectory groups at the end of the 5-year period during which annual eGFR measurements were performed (and thus the start of mortality ascertainment for Cox modelling) are shown in Table 4 . Those with a high/declining eGFR tended to be younger, more sedentary and more likely to be 
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T M E Davis and others EGFR and death in type 2 diabetes insulin-treated than patients with the other three trajectories, but there were no other consistent distinguishing features including therapies for nonglycaemic cardiovascular risk factors and polymorphisms of the ACE, ATR1, APOE and MTHFR genes. During follow-up, 228 (42.9%) of the 532 patients died. All-cause mortality varied from 38.3% in the medium trajectory group to 71.8% in the low trajectory group (Table 4) .
In a Cox model, male gender and albuminuria were both positive independent predictors of death, as was eGFR trajectory, which displaced eGFR category from the most parsimonious model. With medium trajectory as reference (HR = 1.0), both low and high/declining trajectories more than doubled the risk of all-cause mortality (HRs 2.03 (1.30-3.18) and 2.24 (1.31-3 .83) respectively, P ≤ 0.003; Table 5 ). Kaplan-Meier plots by trajectory are shown in Fig. 2 . The median differences in survival versus the medium trajectory were −6.5 and −8.7 years for a low or high/declining trajectory respectively.
Causes of death
The most common cause of death was cardiovascular disease (41%) followed by cancer (26%) with no trends by eGFR trajectory group (Fisher's exact test, P ≥ 0.38). Nearly 5% of deaths were due to renal disease. There was a tendency for this percentage to be higher in the low and high/declining eGFR trajectory groups (11% in both vs 6% in the medium and 2% in the high eGFR trajectory groups; Fisher's exact test, P = 0.064), but the number of deaths due to renal disease was small (n = 11).
Discussion
The present data from the full community-based FDS1 cohort confirm the finding from a large meta-analysis that there is a U-shaped relationship between eGFR and subsequent all-cause death in patients with type 2 diabetes (1). We had access to a variety of risk factors for mortality that were not available in the pooled analysis (1), but the nonlinear independent association with eGFR category remained strong after adjustment. In a separate analysis of longitudinal data collected over 5 years from a large FDS1 sub-group, GBM-based classification of patients by eGFR trajectory proved to be a stronger independent predictor of mortality than simple baseline eGFR category. Both low and high/declining trajectories doubled the risk of subsequent all-cause death relative to a medium trajectory after adjustment for other risk factors, with a median loss of >6 years of life. These observations have important clinical implications, suggesting that the identification of patients with a high/declining phenotype should have a high priority in type 2 diabetes management.
The baseline eGFR associated with the best prognosis in the full FDS1 cohort corresponded to Stage 3 renal impairment (45-59 mL/min/1.73 m 2 ). In the recent metaanalysis, the nadir of the U-shaped relationship between ) (1). The most likely explanation for this discrepancy is patient age. In the majority of studies in the meta-analysis in which, like the FDS1, people with diabetes were identified from a general population, the mean age was younger than in the FDS1 (≤64 years in 13 of 23 studies) (1) including one from Taiwan which was five times the size of the next largest (n = 25 515) and in which the mean patient age was only 56 years (35) . Indeed, binary stratification at age 65 years showed that the U-shaped relationship between eGFR and all-cause death was attenuated in the younger age group (1). The lower nadir in this study is thus likely to reflect the agerelated decline in eGFR, which is independent of chronic kidney disease.
The poor prognosis associated with a low baseline eGFR seen in this study is well established (36) , including diabetes (37) , but the association between a high eGFR and death has been recognised only relatively recently. There are several factors that could underlie this latter relationship. The present patients with an eGFR ≥90 mL/ min/1.73 m 2 may have had a reduced muscle mass, with a consequently low serum creatinine and high eGFR. Sarcopenia is predictive of death in general population studies (38) . An alternative explanation is that the highest eGFR category in FDS1 contained a disproportionately large percentage of patients with hyperfiltration and others may have progressed through this phase before recruitment. In both these cases, there is an increased associated risk of progression to diabetic nephropathy (39) and, if independent associations in the general population apply to diabetes, an increased risk of subclinical and overt cardiovascular disease (40, 41) and allcause death (5) . Support for the latter explanation comes from GBM-defined eGFR trajectories in a large sub-group of FDS1 patients. Along with the low trajectory group in whom a relatively poor prognosis would be expected (37) , the other at-risk patients were those with a high/declining trajectory. The patients in this group tended to be relatively young and insulin-treated, factors which would be against reduced muscle mass, while there was a disproportionately high percentage of hyperfiltrators. In addition, back-extrapolation of the relatively high rate of linear eGFR decline suggests that many patients in this group who had an eGFR below the age-adjusted hyperfiltration threshold at FDS1 entry (when the median diabetes duration was around 5 years) would have passed through a period of hyperfiltration before recruitment. The novel clinical implications of the present data relate to patients with type 2 diabetes who have relatively good renal function. The mean baseline eGFRs in the high and high/declining trajectory groups in this study were similar and close to 90 mL/min/1.73 m 2 . Since the small minority (16%) of these combined groups who are in the high risk high/declining trajectory cannot be readily identified by a range of anthropometric, clinical, laboratory and genetic characteristics, it is important that regular eGFR measurements are performed. Given that the rate of eGFR decline is 2-3 times that of the other three trajectory groups, annual assessments should identify high/declining patients within a few years and afford the opportunity to intensify therapy aimed at optimising control of glycaemia and non-glycaemic cardiovascular risk factors. It is of relevance that only 38.8% of the high/ declining group were statin-treated at the end of the 5-year follow-up period, while only just over one-half were taking renin-angiotensin system blocking drugs. Optimisation of lifestyle factors (more half had a BMI >30 kg/m 2 ) as well as pharmacotherapy may improve prognosis in these patients.
There is evidence that the progression of renal disease in individual patients can be variable, including relatively complex nonlinear changes in eGFR with time (6) . In this study, GBM assigned individual patients to trajectories based on probability and did not exclude those with unusual temporal variability in eGFR. Since eGFR is sensitive to factors such as body weight change, changes in treatment for diabetes and other diseases, and intercurrent illnesses unrelated to diabetes, contextual clinical interpretation of patterns in serial eGFR measures remains an important part of case management (46) . This study found that the degree of albuminuria was a predictor of all-cause mortality independent of eGFR categories both in the full FDS1 cohort and in the subset in whom trajectories were determined. This relationship has been found in the general population (1, 47) as well as type 2 diabetes (1, 48, 49) , and underscores the benefits of including both eGFR and albuminuria in the recently updated renal disease categorisation (45) as well as highlighting the strong links between albuminuria and endothelial function beyond the kidney (50) . The other independent risk factors for all-cause death such as male gender, smoking and prior vascular disease were largely as expected, although the inverse relationship with systolic blood pressure likely reflects the nonlinear association between these two variables described in other studies of type 2 diabetes (51).
This study had limitations. As acknowledged, creatinine-based methods including CKD-EPI tend to underestimate GFR at the high end of the range compared with isotopic measurement (3) and this may have influenced the present analyses, especially in relation to the identification of hyperfiltration. Nevertheless, creatinine-based methods are used widely, including in studies showing a U-shaped relationship between eGFR and death in the general population and in diabetes in particular (1, 2) . Because trajectory categorisation required 5 years of eGFR data, the patients included in this part of the present analyses were young and healthy survivors compared with the FDS1 type 2 sample as a whole. Nevertheless, we had near-complete data and these patients were followed for long enough to accrue endpoints from an established data linkage system that were sufficient to support valid multivariate analyses of mortality. In addition, the non-glycaemic determinants of all-cause mortality were all clinically plausible, including albuminuria.
In conclusion, the present longitudinal data from a large representative community-based cohort of patients with type 2 diabetes confirm the U-shaped relationship between eGFR and subsequent all-cause mortality found in a range of other studies (1), albeit in a cohort with a wide range of potential explanatory and confounding variables not available in the meta-analysis. However, the use of GBM facilitated the identification of a subgroup of patients with an initially relatively high eGFR who exhibited a rapid decline in renal function over the next 5 years and who had a substantially increased risk of death compared with the patients with a similar eGFR at baseline but which remained relatively stable during follow-up. The high/declining group did not have clear differentiating baseline features, but their temporal eGFR profile may be a marker of vulnerability to cardiovascular and other causes of mortality that is not captured by conventional risk factors which were adjusted for in the multivariate models. There is, therefore, the need to monitor eGFR regularly, even in those patients well away from clinically concerning degrees of renal impairment.
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